Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2021 | CML news to look out for at ASH 2021

Francois-Xavier Mahon • 26 Nov 2021

ASH 2021

Chronic Myeloid Leukemia Leukemia Asciminib Nilotinib

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, talks on several chronic myeloid leukemia (CML) abstracts to look at for at the ASH 2021 annual congress. Prof. Mahon highlights asciminib, a first-in-class STAMP inhibitor currently under investigation for CML patients with resistance to previous tyrosine kinase inhibitor (TKI) therapy. Clinical data from several trials using asciminib will be presented. Prof. Mahon also comments on data regarding treatment-free remission after different durations of nilotinib treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Recommendations for treatment discontinuation in CML

Francois-Xavier Mahon • 22 Oct 2022

Design & aims of the EURO-SKI trial in CML

Francois-Xavier Mahon • 22 Oct 2022

Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure

Francois-Xavier Mahon • 22 Oct 2022

Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts

Francois-Xavier Mahon • 26 Nov 2021

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024